The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 3, 2012, Pages 654-660

  Wei, Jing ^a   Pan, Xiangdong ^b   Pei, Zhong ^c   Wang, Weimin ^d   Qiu, Wusi ^d   Shi, Zhenghua ^d   Xiao, Guomin ^d  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b Traditional Chinese Medicine Hospital of Linan   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Ceftriaxone; neuroprotection; rats; traumatic brain injury

Indexed keywords

CEFTRIAXONE; GAMMA INTERFERON; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIEXCITOTOXICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; BRAIN EDEMA; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; LEARNING; MAZE TEST; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BETA-LACTAMS; BIOPSY, NEEDLE; BLOTTING, WESTERN; BRAIN EDEMA; BRAIN INJURIES; CEFTRIAXONE; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID TRANSPORTER 2; IMMUNOHISTOCHEMISTRY; NEUROPROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SURVIVAL RATE; TREATMENT OUTCOME; UP-REGULATION;

EID: 84865955492     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31825133c0     Document Type: Article

References (37)

1. Andriessen TM, Horn J, Franschman G, et al. Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma. 2011;28: 2019-2031.
2. Sande A, West C. Traumatic brain injury: a review of pathophysiology and management. J Vet Emerg Crit Care (San Antonio). 2010;20:177-190.
3. Vink R, Bullock MR. Traumatic brain injury: therapeutic challenges and new directions. Neurotherapeutics. 2010;7:1-2.
4. Loane DJ, Faden AI. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci. 2010;31:596-604.
5. Doppenberg EM, Choi SC, Bullock R. Clinical trials in traumatic brain injury: lessons for the future. J Neurosurg Anesthesiol. 2004;16:87-94.
6. Von Elm E, Schoettker P, Henzi I, Osterwalder J, Walder B. Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence. Br J Anaesth. 2009;103:371-386.
7. McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest. 1996;74:315-342.
8. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int. 2006; 48:394-403.
9. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science. 1989;244: 798-800.
10. Tyurin VA, Tyurina YY, Borisenko GG, et al. Oxidative stress following traumatic brain injury in rats: quantitation of biomarkers and detection of free radical intermediates. J Neurochem. 2000;75:2178-2189.
11. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17:871-890.
12. Ghirnikar RS, Lee YL, Eng LF. Inflammation in traumatic brain injury: role of cytokines and chemokines. Neurochem Res. 1998;23:329-340.
13. Holmin S, Söderlund J, Biberfeld P, Mathiesen T. Intracerebral inflammation after human brain contusion. Neurosurgery. 1998;42:291-298.
14. Frugier T, Morganti-Kossmann MC, O'Reilly D, McLean CA. In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma. 2010;27:497-507.
15. Israelsson C, Wang Y, Kylberg A, Pick CG, Hoffer BJ, Ebendal T. Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. J Neurotrauma. 2009;26:1307-1314.
16. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 2004;14:215-222.
17. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010;23:293-299.
18. Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005;22:3-41.
19. Van Landeghem FK, Stover JF, Bechmann I, et al. Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia. 2001;35:167-179.
20. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333-355.
21. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia. 2002;32:1-14.
22. Gardoni F, Ghiglieri V, Luca M, Calabresi P. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog Brain Res. 2010;183:169-182.
23. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73-77.
24. Lipski J, Wan CK, Bai JZ, Pi R, Li D, Donnelly D. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience. 2007;146: 617-629.
25. Hedlund E. The protective effects of A-lactam antibiotics in motor neuron disorders. Exp Neurol. 2011;231:14-18.
26. Verma R, Mishra V, Sasmal D, Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol. 2010;638:65-71.
27. Nizzardo M, Nardini M, Ronchi D, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol. 2011;229:214-225.
28. Chu K, Lee ST, Sinn DI, et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke. 2007;38:177-182.
29. Miller BR, Dorner JL, Shou M, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience. 2008;153:329-337.
30. Kim K, Lee SG, Kegelman TP, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol. 2011;226:2484-2493.
31. Feeney DM, Boyeson MG, Linn RT, Murray HM, Dail WG. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res. 1981;211:67-77.
32. Dellu F, MayoW, Cherkaoui J, Le Moal M, Simon H. A two-trial memory task with automated recording: study in young and aged rats. Brain Res. 1992;588:132-139.
33. Li DQ, Duan YL, Bao YM, Liu CP, Liu P. An LJ. Neuroprotection of catalpol in transient global ischemia in gerbils. Neurosci Res. 2004;50: 169-177.
34. Van Landeghem FK, Weiss T, Oehmichen M, Von Deimling A. Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma. 2006;23:1518-1528.
35. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol. 2005;90:663-670.
36. O'Connor WT, Smyth A, Gilchrist MD. Animal models of traumatic brain injury: a critical evaluation. Pharmacol Ther. 2011;130:106-113.
37. Thöne-Reineke C, Neumann C, Namsolleck P, et al. The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens. 2008;26: 2426-2435.